Table 2.
Determination of initial (t½α) and terminal (t½β) half-lives as well as of drug exposure (area under the curve; AUC) of bispecific Db3-43xhu225-Ig molecules. Mean ± SD, n = 3.
| antigen | Db3-43xhu225-CH1/CL-Fc | Db3-43xhu225-EHD2-Fc | Db3-43xhu225-hetEHD2-Fc | Db3-43xhu225-MHD2-Fc | |
|---|---|---|---|---|---|
| t½α [h] | EGFR | 3.0 ± 0.7 | 3.4 ± 1.9 | 1.4 ± 0.1 | 0.9 ± 0.1 |
| HER3 | 3.3 ± 1.3 | 2.6 ± 0.5 | 3.9 ± 3.7 | 1.8 ± 0.5 | |
| t½β [h] | EGFR | 89 ± 3 | 105 ± 16 | 64 ± 14 | 74 ± 8 |
| HER3 | 86 ± 3 | 95 ± 5 | 48 ± 4 | 71 ± 2 | |
| AUC [%·h] | EGFR | 3,899 ± 533 | 4,467 ± 1010 | 3,442 ± 380 | 3,014 ± 666 |
| HER3 | 3,695 ± 621 | 3,768 ± 388 | 2,603 ± 364 | 3,727 ± 395 |